e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aptose Biosciences, Inc. - Common Shares
(TSX:
APS
)
2.000
+0.230 (+12.99%)
Streaming Delayed Price
Updated: 9:56 AM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,422
Open
1.770
Bid (Size)
1.690 (14)
Ask (Size)
2.000 (1)
Prev. Close
1.770
Today's Range
1.770 - 2.030
52wk Range
0.1550 - 5.800
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
October 16, 2025
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
September 22, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Performance
YTD
+506.1%
+506.1%
1 Month
+17.6%
+17.6%
3 Month
-10.7%
-10.7%
6 Month
-39.4%
-39.4%
1 Year
+312.4%
+312.4%
More News
Read More
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
August 22, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
August 18, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Second Quarter 2025 Results
August 13, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
August 06, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
August 01, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
July 15, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Upgraded to Trade on OTCQB Market
July 01, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Deferral of Interest Payment
June 30, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
June 20, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Provides Corporate Updates
June 17, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
June 12, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
May 27, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
May 20, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
May 14, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports First Quarter 2025 Results
May 08, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
May 05, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Auditor Not Standing for Re-Appointment
April 23, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 23, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
April 01, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Year End 2024 Results and Corporate Highlights
March 28, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
March 17, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
February 20, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Reverse Share Split
February 18, 2025
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Aptose Biosciences, Inc. - Common Shares publicly traded?
Yes, Aptose Biosciences, Inc. - Common Shares is publicly traded.
What exchange does Aptose Biosciences, Inc. - Common Shares trade on?
Aptose Biosciences, Inc. - Common Shares trades on the Toronto Stock Exchange
What is the ticker symbol for Aptose Biosciences, Inc. - Common Shares?
The ticker symbol for Aptose Biosciences, Inc. - Common Shares is APS on the Toronto Stock Exchange
What is the current price of Aptose Biosciences, Inc. - Common Shares?
The current price of Aptose Biosciences, Inc. - Common Shares is 2.000
When was Aptose Biosciences, Inc. - Common Shares last traded?
The last trade of Aptose Biosciences, Inc. - Common Shares was at 10/17/25 09:56 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.